<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301169</url>
  </required_header>
  <id_info>
    <org_study_id>T1001-01</org_study_id>
    <nct_id>NCT02301169</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effects of a New Treatment in Patients With Chronic Pain</brief_title>
  <official_title>A Study to Investigate the Effects of T4P1001 Treatment in Patients With Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tools4Patient</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tools4Patient</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial conducted in patients suffering from chronic pain is to
      study the relationship between individual patients' profile and their analgesic response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment</measure>
    <time_frame>Time zero equals baseline (Day 1) up to Day 42</time_frame>
    <description>11-point Numeric Rating Scale (NRS). Scale from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine. Lower values represent a better outcome. Unit: arithmetic average of 7 days of a 11-point NRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Worst Pain Scores (WPS)</measure>
    <time_frame>Time zero equals baseline (Day 1) up to Day 42</time_frame>
    <description>11-point Numeric Rating Scale (NRS) Scale from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine. Lower values represent a better outcome. Unit: arithmetic average of 7 days of a 11-point NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Change From Baseline of Investigator Global Assessment of Change (IGAC)</measure>
    <time_frame>Time zero equals baseline (Day 1) up to Day 28</time_frame>
    <description>IGAC is an investigator subjective evaluation of patient condition using a NRS from 0 to 10 with 0 meaning best and 10 worst Lower values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Change of Pain Intensity After Heat Pain Stimuli From Baseline to End of Treatment Period</measure>
    <time_frame>Time zero equals baseline (Day 1) up to Day 28</time_frame>
    <description>11-point Numeric Rating Scale (NRS) from 0 to 10; 0 meaning no pain, 10 pain as bad as you can imagine Lower values represent a better outcome Unit: arithmetic average on 6 reported scores per Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Brief Pain Inventory (BPI).</measure>
    <time_frame>Time zero equals baseline (Day 1) up to Day 28</time_frame>
    <description>Arithmetic average of 3 questions on an 11-point Numeric Rating Scale (NRS) from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine.
Lower values represent a better outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Peripheral Neuropathies</condition>
  <arm_group>
    <arm_group_label>T4P1001</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Heat pain stimuli A</intervention_name>
    <arm_group_label>T4P1001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Video A</intervention_name>
    <arm_group_label>T4P1001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of T4P1001 capsules</intervention_name>
    <description>This treatment is given as add on therapy to patients' regular analgesic</description>
    <arm_group_label>T4P1001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Heat pain stimuli B</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Video B</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of placebo capsules</intervention_name>
    <description>This treatment is given as add on therapy to patients' regular analgesic</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women of at least 18 years of age

          -  Body weight of more than 40 kg and less than 120 kg with a BMI between 19-31 kg/m2
             inclusive

          -  Diagnosed with Peripheral Neuropathic Pain (PNP) since at least 6 months

          -  Being affiliated with the national welfare system

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

          -  Have given written informed consent approved by the relevant Ethics Committee (EC)
             governing the study site

        PNP disease diagnosis inclusion criteria:

          -  Patient with chronic PNP supported by a distinct neuroanatomical plausible
             distribution with sensory signs and symptoms, and consecutive to one of the following
             causes: a traumatic event, a surgical procedure (excluding limb amputation),
             radiculopathy, post-herpetic or post-zooster neuralgia, diabetic polyneuropathy or
             post-anticancer chemotherapy. Diagnosis will have to be confirmed by the DN4
             questionnaire at the screening visit (pain is considered as neuropathic if DN4 score â‰¥
             4)

          -  Pain present since at least 6 months

          -  Patients will be required to have a score between 4 and 8 inclusive on the mean
             Average Pain Score (APS) Numeric Rating Scale (NRS) during the baseline period
             preceding randomization (data collected in patient diary) and to have completed at
             least 4 days of pain assessment

        Exclusion Criteria:

          -  Pregnant, breastfeeding, or willing to be pregnant within 2 months

          -  With a current or recent history, as determined by the Investigator, of severe,
             progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal,
             endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere
             with the patient's participation in the study

          -  Uncontrolled epilepsy

          -  Any current primary psychiatric condition, including major depression or major
             personality disorders (such as Axe II of Diagnostic and Statistical Manual of Mental
             Disorders (DSM-IV); personality disorders and mental retardation)

          -  Alcohol dependence or regular use of known drugs of abuse (e.g., amphetamines,
             barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, and
             phencyclidine)

          -  Acute disease state within 7 days before Visit 2

          -  Any other relevant medical disorder likely to interfere with the trial or represent a
             risk for the patient

          -  Any close relationship with the Investigators or the Sponsor (i.e. belonging to
             immediate family or subordination link)

          -  Patient under legal protection, according to the national law

          -  Patient currently enrolled in a clinical trial involving use of an investigational
             drug or device, or concurrently enrolled in any other type of medical research judged
             not to be scientifically or medically compatible with this study, or in an exclusion
             period according to national law

        Exclusion criteria related to PNP:

          -  Neuropathic pain due to trigeminal neuralgia, central pain, complex regional pain
             syndrome and phantom limb pain

          -  Plan to have a session of physiotherapy or comportemental therapy such as gestion of
             pain, hypnosis, sophrology, meditation program during the study

          -  Have initiated or have planned an electrical stimulation (or neurostimulation) therapy
             within 2 weeks prior to Visit 1 or during the study period up to Visit 5

          -  Patient changed his/her &quot; regular therapy &quot; in the last 4 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alvaro Pereira</last_name>
    <role>Study Director</role>
    <affiliation>Tools4Patient</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC Clermont-Ferrand, CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <results_first_submitted>December 7, 2015</results_first_submitted>
  <results_first_submitted_qc>April 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2016</results_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T4P1001</title>
          <description>Heat pain stimuli A
Video A
Administration of T4P1001 capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Heat pain stimuli B
Video B
Administration of placebo capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T4P1001</title>
          <description>Heat pain stimuli A
Video A
Administration of T4P1001 capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Heat pain stimuli B
Video B
Administration of placebo capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="10.3"/>
                    <measurement group_id="B2" value="55.5" spread="12.7"/>
                    <measurement group_id="B3" value="56.8" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment</title>
        <description>11-point Numeric Rating Scale (NRS). Scale from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine. Lower values represent a better outcome. Unit: arithmetic average of 7 days of a 11-point NRS</description>
        <time_frame>Time zero equals baseline (Day 1) up to Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T4P1001</title>
            <description>Heat pain stimuli A
Video A
Administration of T4P1001 capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Heat pain stimuli B
Video B
Administration of placebo capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
          </group>
        </group_list>
        <measure>
          <title>Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment</title>
          <description>11-point Numeric Rating Scale (NRS). Scale from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine. Lower values represent a better outcome. Unit: arithmetic average of 7 days of a 11-point NRS</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="1.49"/>
                    <measurement group_id="O2" value="0.5" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: no difference in mean change from baseline to day 42 of pain severity as measured by weekly means of the daily Average Pain Score (APS), T4P1001 compared with placebo</non_inferiority_desc>
            <p_value>0.4162</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. The a priori level of significance was specified to be 0.05 for between-treatment group comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Welch two sample t-test</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3748299</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5479411</ci_lower_limit>
            <ci_upper_limit>1.2976010</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Worst Pain Scores (WPS)</title>
        <description>11-point Numeric Rating Scale (NRS) Scale from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine. Lower values represent a better outcome. Unit: arithmetic average of 7 days of a 11-point NRS</description>
        <time_frame>Time zero equals baseline (Day 1) up to Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T4P1001</title>
            <description>Heat pain stimuli A
Video A
Administration of T4P1001 capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Heat pain stimuli B
Video B
Administration of placebo capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
          </group>
        </group_list>
        <measure>
          <title>Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Worst Pain Scores (WPS)</title>
          <description>11-point Numeric Rating Scale (NRS) Scale from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine. Lower values represent a better outcome. Unit: arithmetic average of 7 days of a 11-point NRS</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="1.45"/>
                    <measurement group_id="O2" value="0.65" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: no difference in mean change from baseline to day 42 of pain severity as measured by weekly means of the daily Worst Pain Score (WPS), T4P1001 compared with placebo.</non_inferiority_desc>
            <p_value>0.7887</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. The a priori level of significance was specified to be 0.05 for between-treatment group comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Welch two sample t-test</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1255102</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8152493</ci_lower_limit>
            <ci_upper_limit>1.0662697</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Change From Baseline of Investigator Global Assessment of Change (IGAC)</title>
        <description>IGAC is an investigator subjective evaluation of patient condition using a NRS from 0 to 10 with 0 meaning best and 10 worst Lower values represent a better outcome.</description>
        <time_frame>Time zero equals baseline (Day 1) up to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T4P1001</title>
            <description>Heat pain stimuli A
Video A
Administration of T4P1001 capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Heat pain stimuli B
Video B
Administration of placebo capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Change From Baseline of Investigator Global Assessment of Change (IGAC)</title>
          <description>IGAC is an investigator subjective evaluation of patient condition using a NRS from 0 to 10 with 0 meaning best and 10 worst Lower values represent a better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="1.755"/>
                    <measurement group_id="O2" value="-0.95" spread="2.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: no difference in mean change from baseline to day 42 of pain severity as measured by Investigator Global Assessment of Change, T4P1001 compared with Placebo</non_inferiority_desc>
            <p_value>0.2353</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. The a priori level of significance was specified to be 0.05 for between-treatment group comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Welch two sample t-test</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.802381</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5457743</ci_lower_limit>
            <ci_upper_limit>2.1505362</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Change of Pain Intensity After Heat Pain Stimuli From Baseline to End of Treatment Period</title>
        <description>11-point Numeric Rating Scale (NRS) from 0 to 10; 0 meaning no pain, 10 pain as bad as you can imagine Lower values represent a better outcome Unit: arithmetic average on 6 reported scores per Visit.</description>
        <time_frame>Time zero equals baseline (Day 1) up to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T4P1001</title>
            <description>Heat pain stimuli A
Video A
Administration of T4P1001 capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Heat pain stimuli B
Video B
Administration of placebo capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Change of Pain Intensity After Heat Pain Stimuli From Baseline to End of Treatment Period</title>
          <description>11-point Numeric Rating Scale (NRS) from 0 to 10; 0 meaning no pain, 10 pain as bad as you can imagine Lower values represent a better outcome Unit: arithmetic average on 6 reported scores per Visit.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="1.003"/>
                    <measurement group_id="O2" value="-0.01" spread="1.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: no difference in mean change from baseline to day 42 of pain intensity measured after heat pain stimuli, T4P1001 compared with placebo.</non_inferiority_desc>
            <p_value>0.06204</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. The a priori level of significance was specified to be 0.05 for between-treatment group comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Welch two sample t-test</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.7656429</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0406744</ci_lower_limit>
            <ci_upper_limit>1.5719601</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Brief Pain Inventory (BPI).</title>
        <description>Arithmetic average of 3 questions on an 11-point Numeric Rating Scale (NRS) from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine.
Lower values represent a better outcome</description>
        <time_frame>Time zero equals baseline (Day 1) up to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T4P1001</title>
            <description>Heat pain stimuli A
Video A
Administration of T4P1001 capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Heat pain stimuli B
Video B
Administration of placebo capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
          </group>
        </group_list>
        <measure>
          <title>Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Brief Pain Inventory (BPI).</title>
          <description>Arithmetic average of 3 questions on an 11-point Numeric Rating Scale (NRS) from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine.
Lower values represent a better outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="5.422"/>
                    <measurement group_id="O2" value="1.67" spread="5.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: no difference in mean change from baseline to day 42 of pain severity as measured by the Brief Pain Inventory (BPI), T4P1001 compared with placebo.</non_inferiority_desc>
            <p_value>0.3386</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. The a priori level of significance was specified to be 0.05 for between-treatment group comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Welch two sample t-test</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.683333</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.831190</ci_lower_limit>
            <ci_upper_limit>5.197857</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>T4P1001</title>
          <description>Heat pain stimuli A
Video A
Administration of T4P1001 capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Heat pain stimuli B
Video B
Administration of placebo capsules: This treatment is given as add on therapy to patients' regular analgesic</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Specific agreement as part of Eureka project</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie Alvarez</name_or_title>
      <organization>Tools4Patient</organization>
      <phone>+32 71 14 ext 02 00</phone>
      <email>stephanie.alvarez@tools4patient.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

